Herein, CD86 was immunohistochemically detected in 36 of the 255 patients (14.1%), which is similar to nasopharyngeal carcinoma patients (20.0%) [25] and lower in non-small cell lung cancer (NSCLC) patients (53%) [26]. This evidence concerns the gene CD86 and nasopharyngeal carcinoma.